{"id":954809,"date":"2026-04-27T09:32:20","date_gmt":"2026-04-27T13:32:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/"},"modified":"2026-04-27T09:32:20","modified_gmt":"2026-04-27T13:32:20","slug":"allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/","title":{"rendered":"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:center\">\n          <i>Patent expected to be formally granted within three months, subject to standard administrative procedures<br \/><\/i><br \/>\n          \n        <\/li>\n<li style=\"text-align:center\">\n          <i>Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test<br \/><\/i><br \/>\n          \n        <\/li>\n<\/ul>\n<p>\n        <b>TARPON SPRINGS, Fla., <\/b>April 27, 2026 \u2013 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)\u2014a differentiated, dual PARP and WNT pathway inhibitor\u2014 today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company\u2019s DRP<sup>\u00ae<\/sup> companion diagnostic specific to stenoparib.<\/p>\n<p>Importantly, this Notice of Allowance covers multiple claims and represents a major step in Allarity\u2019s global strategy to expand and protect the commercial potential of stenoparib when selecting patients using its proprietary stenoparib DRP<sup>\u00ae<\/sup> test. The patent is expected to be formally granted within three months, subject to standard administrative procedures and would provide exclusivity at least into 2039 for stenoparib when used in concert with the DRP<sup>\u00ae<\/sup> as a companion diagnostic.<\/p>\n<p>Thomas Jensen, CEO of Allarity Therapeutics, commented: \u201cThis Notice of Allowance from the USPTO represents another successful milestone in our efforts to secure intellectual property protection for our DRP\u00ae technology in the US, the world\u2019s most important pharmaceutical market. Critically, this patent maximizes the marketing exclusivity in the US for stenoparib in patients selected using the stenoparib DRP test, which is especially important as we seek to accelerate stenoparib toward approval for Ovarian and other cancers.\u201d<\/p>\n<p>The allowed claims include methods for predicting clinical benefit based on gene expression profiles derived from tumor samples and for selecting those patients most likely to benefit from stenoparib treatment.<\/p>\n<p>Allarity previously secured a European and Australian patent for the Stenoparib DRP<sup>\u00ae<\/sup>\u00a0and holds 18 granted patents for other drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP<sup>\u00ae<\/sup>\u00a0remain pending in Canada, Japan, China, and India.<\/p>\n<p>\n        <b>About Stenoparib\/2X-121<\/b><br \/>\n        <br \/>Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1\/2 and tankyrase 1\/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT\/\u03b2-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib\u2019s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, Small Cell Lung Cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in Ovarian Cancer patients. In the first, patients who had had 2+ lines of therapy were enrolled on stenoparib and given drug twice daily. This protocol has been closed to further enrollment but continues for the enrolled patients who are still receiving benefit from stenoparib administration. The updated data from this study were presented at the AACR special conference on advances in Ovarian Cancer in September 2025. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. An amended protocol designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum resistant patients began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval. In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently enrolling patients across multiple U.S. Veterans Administration (VA) sites.<\/p>\n<p><b>About the Drug Response Predictor \u2013 DRP<\/b><sup><b>\u00ae<\/b><\/sup><b> Companion Diagnostic<\/b><br \/>Allarity uses its drug-specific DRP<sup>\u00ae<\/sup>\u00a0to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP<sup>\u00ae<\/sup>\u00a0platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.<\/p>\n<p><b>About Allarity Therapeutics<\/b><br \/>Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP\/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP<sup>\u00ae<\/sup>\u00a0technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EuL4MyqzvpeuSGxE7GixLMLpnyOfCTduNIFXqrhbswPgxcM8XRAZJNk1ePX2JkYPB1p7PbtWwYUvCgh9HHmbvi1nzsrgCdEzGw4loLrpKoo=\" rel=\"nofollow\" target=\"_blank\">www.allarity.com<\/a>.<\/p>\n<p>\n        <b>Follow Allarity on Social Media<\/b><br \/>\n        <br \/>LinkedIn: https:\/\/www.linkedin.com\/company\/allaritytx\/<\/p>\n<p>\n        <b>Forward-Looking Statements <\/b><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company\u2019s current expectations or forecasts of future events. The words \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected grant and scope of the U.S. patent for the stenoparib DRP\u00ae companion diagnostic; the anticipated contribution of this patent to the Company\u2019s global intellectual property strategy; and the Company\u2019s ability to advance and commercialize stenoparib and its companion diagnostic. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the patent grant process, including potential delays or challenges; the Company\u2019s ability to obtain, maintain, and enforce intellectual property protection; and broader risks related to the Company\u2019s clinical development, regulatory progress, and financial resources. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in our Form 10-K annual report filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 30, 2026, available at the SEC\u2019s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company\u2019s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.<\/p>\n<p align=\"center\">###<\/p>\n<p>Company Contact: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>\u00a0 \u00a0 \u00a0 \u00a0 investorrelations@allarity.com<\/p>\n<p>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Media Contact:<br \/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Thomas Pedersen<br \/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Carrotize PR &amp; Communications<br \/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0+45 6062 9390<br \/>\u00a0 \u00a0 \u00a0 \u00a0 tsp@carrotize.com<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/2cf77e8a-17c5-4f0b-ad7f-926b11acc3fa\">Allarity Therapeutics Press Release &#8211; Stenoparib DRP Test Has Received a Notice of Allowance from the USPTO<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NzYwM2M0ZDMtYmY3Zi00OTc1LThkMjMtNjQxMjQ0MTVkZWI4LTEwMTI2NzgtMjAyNi0wNC0yNy1lbg==\/tiny\/Allarity-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test TARPON SPRINGS, Fla., April 27, 2026 \u2013 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)\u2014a differentiated, dual PARP and WNT pathway inhibitor\u2014 today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company\u2019s DRP\u00ae companion diagnostic specific to stenoparib. Importantly, this Notice of Allowance covers multiple claims and represents a major step in Allarity\u2019s global strategy to expand and protect the commercial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954809","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test TARPON SPRINGS, Fla., April 27, 2026 \u2013 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)\u2014a differentiated, dual PARP and WNT pathway inhibitor\u2014 today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company\u2019s DRP\u00ae companion diagnostic specific to stenoparib. Importantly, this Notice of Allowance covers multiple claims and represents a major step in Allarity\u2019s global strategy to expand and protect the commercial &hellip; Continue reading &quot;Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T13:32:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office\",\"datePublished\":\"2026-04-27T13:32:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/\"},\"wordCount\":1266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/\",\"name\":\"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==\",\"datePublished\":\"2026-04-27T13:32:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/","og_locale":"en_US","og_type":"article","og_title":"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Market Newsdesk","og_description":"Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP test TARPON SPRINGS, Fla., April 27, 2026 \u2013 Allarity Therapeutics, Inc. (\u201cAllarity\u201d or the \u201cCompany\u201d) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)\u2014a differentiated, dual PARP and WNT pathway inhibitor\u2014 today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company\u2019s DRP\u00ae companion diagnostic specific to stenoparib. Importantly, this Notice of Allowance covers multiple claims and represents a major step in Allarity\u2019s global strategy to expand and protect the commercial &hellip; Continue reading \"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-27T13:32:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office","datePublished":"2026-04-27T13:32:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/"},"wordCount":1266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/","name":"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==","datePublished":"2026-04-27T13:32:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE3ODEzMCM0MDIzODE0OTQjMjAwMTEwNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allarity Therapeutics Announces that the Stenoparib DRP\u00ae Test Has Received a Notice of Allowance from the US Patent and Trademark Office"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954809"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954809\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}